88 related articles for article (PubMed ID: 20096949)
1. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction.
Ban CR; Twigg SM; Franjic B; Brooks BA; Celermajer D; Yue DK; McLennan SV
Diabetes Res Clin Pract; 2010 Mar; 87(3):335-41. PubMed ID: 20096949
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
3. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
Jacqueminet S; Ben Abdesselam O; Chapman MJ; Nicolay N; Foglietti MJ; Grimaldi A; Beaudeux JL
Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
[TBL] [Abstract][Full Text] [Related]
4. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
5. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
6. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
[TBL] [Abstract][Full Text] [Related]
7. Abnormal circulating levels of matrix metalloproteinases and their inhibitors in diabetes mellitus.
Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Ftouhi B; Feki M; Slimane H; Kaabachi N
Clin Lab; 2012; 58(7-8):779-85. PubMed ID: 22997979
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
9. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
11. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
13. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions.
Zaoui P; Cantin JF; Alimardani-Bessette M; Monier F; Halimi S; Morel F; Cordonnier D
Diabetes Metab; 2000 Jul; 26 Suppl 4():25-9. PubMed ID: 10922970
[TBL] [Abstract][Full Text] [Related]
14. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
[TBL] [Abstract][Full Text] [Related]
15. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
16. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy.
Van Linthout S; Seeland U; Riad A; Eckhardt O; Hohl M; Dhayat N; Richter U; Fischer JW; Böhm M; Pauschinger M; Schultheiss HP; Tschöpe C
Basic Res Cardiol; 2008 Jul; 103(4):319-27. PubMed ID: 18347835
[TBL] [Abstract][Full Text] [Related]
17. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
18. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
20. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
